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Abstract
Background: Epidemiological evidence suggests that synchronous or metachronous presentation of breast and
thyroid cancers exceeds that predicted by chance alone. The following potential explanations have been
hypothesized: common environmental or hormonal factors, oncogenic effect of the treatment for the first cancer,
closer follow-up of cancer survivors, shared underlying genetic risk factors. While some cases were found to be
related to monogenic disorders with autosomal inheritance, the genetic background of most cases of co-occurring
breast and thyroid cancer is thought to be polygenic.
Methods: In this retrospective case-control study we compared the genetic profile of patients with a history of
breast cancer (n = 15) to patients with co-occurring breast and thyroid cancer (n = 19) using next generation
sequencing of 112 hereditary cancer risk genes. Identified variants were categorized based on their known
association with breast cancer and oncogenesis in general.
Results: No difference between patients with breast and double cancers was observed in clinical and pathological
characteristics or the number of neutral SNPs. The unweighted and weighted number of SNPs with an established
or potential association with breast cancer was significantly lower in the group with breast cancer only (mean
difference − 0.58, BCa 95% CI [− 1.09, − 0.06], p = 0.029, and mean difference − 0.36, BCa 95% CI [− 0.70, − 0.02], p =
0.039, respectively). The difference was also significant when we compared the number of SNPs with potential or
known association with any malignancy (mean difference − 1.19, BCa 95% CI [− 2.27, − 0.11], p = 0.032 for
unweighted, and mean difference − 0.73, BCa 95% CI [− 1.32, − 0.14], p = 0.017 for weighted scores).
Conclusion: Our findings are compatible with the hypothesis of genetic predisposition in the co-occurrence of
breast and thyroid cancer. Further exploration of the underlying genetic mechanisms may help in the identification
of patients with an elevated risk for a second cancer at the diagnosis of the first cancer.
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Background
An increased co-occurrence of breast cancer (BC) and differ-
entiated thyroid cancer (TC) compared to chance alone has
been found repeatedly in recent decades [1, 2]. Numerous
studies have shown a bidirectional association between these
cancers: a more pronounced risk of thyroid cancer in breast
cancer survivors and a less pronounced increase in the inci-
dence of breast cancer after thyroid cancer [2–4].
A number of hypotheses have been suggested to ex-
plain these findings [3, 4]. The one, most frequently
cited, describes a common (yet unknown) hormonal
etiologic factor. This hypothesis is supported by the ob-
servation of a strong female predominance of both
tumor types. Estrogen has been implicated in the patho-
genesis of both breast and, to a lesser degree, thyroid
cancer [5]. Furthermore, thyroid dysfunction has also
been tentatively linked to carcinogenesis [6–8]. It is also
possible that the hormonal milieu of pregnancy (hCG,
increased TRH and prolactin) would increase the thyroid
and the estrogen-like effects of thyroid hormones, hence
the risk of both cancer types [9]. Endocrine disrupting
chemicals affecting estrogen receptors have also been
theoretically implicated [10].
Another set of hypotheses emphasize carcinogenic ef-
fects of previous cancer treatment. Radio- and hormone
therapy for breast cancer and I131 treatment for thyroid
tumors have both been implicated in carcinogenesis
[11–13]. It is also possible that the increased surveillance
of cancer survivors could lead to earlier recognition or
even overdiagnosis of a second primary malignancy.
A shared genetic background of these cancers is also a po-
tential explanation for the observed association. Cowden and
Cowden-like syndromes are characterized by the presence of
hamartomas and an increased risk of, among others, both
thyroid and breast cancer. These conditions are mostly
monogenic disorders with an autosomal dominant inherit-
ance. Mutations in the PTEN, SDHB, SDHD, MTHFR and
PARP4 genes, and hypermethylation of KLLN have all been
implicated [14–16]. Much less is known about the genetic
background of sporadic cases of metachronous or synchron-
ous breast and thyroid cancer. However, an increased famil-
ial risk of other primary malignancies of affected patients
points towards underlying germline mutations [3, 17].
In the present paper, we investigated the potential for
a shared genetic background of thyroid and breast can-
cers. The recognition and elucidation of such genetic
risk factors could aid in the identification, follow-up, and
potential preventive treatment of high-risk individuals
with a first primary malignancy.
Methods
Patients and setting
We analyzed the genetic polymorphisms in 112 heredi-
tary cancer risk genes in a case-control study of patients
with a history of either breast or both breast and thyroid
cancer.
Patients were selected from a pool of n = 274 thyroid
cancer patients who had received I131 treatment at our
institution between January 2014 and October 2018.
Twenty-one of these individuals received treatment for
breast cancer before or after the diagnosis of a thyroid
cancer. Two patients could not have been reached for
consent, resulting in a final sample of 19. Given that the
risk of thyroid cancer development after breast cancer is
larger than vice versa, the control group consisted of 15
subjects who received treatment for breast cancer at our
institution at least 12 years before the present study. Pa-
tients with a personal or a family history of thyroid can-
cer were excluded from this group. These criteria were
specified to minimize contamination of the control
group with patients with an increased genetic risk for
thyroid cancer development. No other inclusion or ex-
clusion criteria were set.
We collected the following clinical characteristics
from hospital and outpatient records: age at cancer
diagnosis, tumor size, histology, staging and grading,
presence or absence of lymph node and distant
metastases, details of surgical-, radiation- chemothera-
peutic-, hormonal and I131 treatment. Cancer diagno-
sis for all cases was based on histological data using
the WHO classification of breast and endocrine tu-
mors (4th and 3/4th edition respectively). Staging was
based on the TNM system (7th edition). Informed
consent was obtained from all subjects before any
study related procedures were performed. The study
was approved by Semmelweis University Regional and
Institutional Committee of Science and Research
Ethics.
Genetic analysis
We have aimed to cover all the well-established heredi-
tary cancer risk loci. The final list of the 112 investigated
genes was compiled based on literature data [18–20],
and is shown in Table 1.
Exome amplicon library was prepared using the Ion
AmpliSeq Library Kit Plus combined with the Ion
AmpliSeq Exome RDY kit (ThermoFisher, MA, USA).
Briefly, 100 ng of genomic DNA was added to dried
down, ultra-high multiplexed primer pairs (12 pools) in
a 96-well plate and amplified with the following PCR
conditions: at 99 °C for 2 min; at 99 °C for 15 s and at
60 °C for 16 min (10 cycles) and holding at 10 °C.
Primers were partially digested using a FuPa reagent,
and then sequencing adapters and barcodes were ligated
to the amplicons. The library was purified using the
Agencourt AMPure XP Reagent (Beckmann Coulter,
CA, USA). The concentration of the final library was de-
termined by Ion Library TaqMan Quantitation Kit
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(ThermoFisher, MA, USA) on an ABI 7500 qPCR instru-
ment with absolute quantification method.
Template preparation was performed with Ion 540
OT2 Kit (ThermoFisher, MA, USA) on semi-automated
Ion OneTouch 2 instrument using emPCR method.
After breaking the emulsion, the non-templated beads
were removed from the solution during the semi-
automated enrichment process on Ion OneTouch ES
(ThermoFisher, MA, USA) machine. Later adding the
sequencing primer and polymerase, the fully prepared
Ion Sphere Particles (ISPs) were loaded into an Ion 540
chip, and the sequencing runs were performed using the
Ion S5 Sequencing kit (ThermoFisher, MA, USA) with
500 flows.
Sequence data from the Ion Torrent run were analyzed
using the platform-specific pipeline software Torrent
Suite v5.10 for base calling, trim adapter and primer se-
quences, filtering out poor quality reads, and de-
multiplex the reads according to the barcode sequences.
Briefly, TMAP algorithm was used to align the reads to
the hg19 human reference genome, and then, the variant
caller plug-in was executed to search for germline vari-
ants in the targeted regions. Integrative genomics viewer
(IGV) was used for visualization of the mapped reads.
Variants were annotated using the Ion Reporter (Ther-
moFisher, MA, USA) software. Variant interpretation
was restricted to the selected genes with known connec-
tion to oncology diseases. Variants were stratified by
gene association with breast cancer and by variant asso-
ciation with cancer (no/potential/known) based on avail-
able data from the ClinVar database at the time of
writing [21]. Synonymous mutations were not excluded
from the analysis.
Statistical analysis
Descriptive data are given as means ± standard deviation
(SD) for continuous data, and frequencies (percentages)
for categorical variables. Between-group differences in
clinical parameters were assessed using 2-sample t tests
for continuous variables, and χ2 tests or Fisher exact
tests for categorical variables.
When comparing the number of different variants
across groups, the assumptions of normality and homo-
geneity of variances were assessed using the Shapiro–
Wilk test and Levene’s test respectively. Given that in
some cases these assumptions were not met, Welch’s t-
test was used to compare the number of variants with
known, potential or no association with breast cancer
and with any cancer. We also used the bootstrap proced-
ure to get robust confidence intervals and p-values. To
increase statistical power, we lumped together variants
with potential and known associations using both
weighted and unweighted scores. To generate the
weighted scores, we gave double weight for variants with
known association compared to those variants with po-
tential association. To correct for multiple testing we ap-
plied the Benjamini-Hochberg procedure targeting a
false discovery rate < 15%. A corrected two-tailed p-value
less than 0.05 was considered statistically significant. Ef-
fect sizes were computed as adjusted standardized mean
differences (Hedge’s g). Analyses were conducted using
IBM SPSS Statistics for Windows, Version 23.0 (IBM
Corp. Released 2015 Armonk, New York, U.S.A.).
Results
Table 2 displays patients’ clinical characteristics. BC only
patients had a slightly younger age at the time of breast
Table 1 List of cancer risk genes assessed. BC associated genes are underlined
ACD CDKN1B FANCA JAGN1 NFIX PTEN TERC
AIP CDKN2A FANCB KIF1B NHP2 RAD50 TERT
APC CHEK2 FANCC KIT NOP10 RAD51 TINF2
ATM DDB2 FANCD2 MAX NSD1 RAD51C TMEM127
ATR DICER1 FANCE MDH2 NTHL1 RAD51D TP53
AXIN2 DIS3L2 FANCF MEN1 PALB2 RB1 TSC1
BAP1 DKC1 FANCG MET PARN RECQL TSC2
BARD1 ELANE FANCI MITF PDGFRA RECQL4 UBE2T
BLM EPAS1 FANCL MLH1 PMS1 RET VHL
BMPR1A EPCAM FANCM MNX1 PMS2 RTEL1 VPS45
BRCA1 ERCC1 FH MSH2 POLD1 SCG5 WAS
BRCA2 ERCC2 FLCN MSH6 POLE SLX4 WRN
BRIP1 ERCC3 G6PC3 MSR1 POLH SMAD4 WT1
BUB1 ERCC4 GFI1 MUTYH POT1 SMARCA4 XPA
CDH1 ERCC5 GREM1 NBN PRKAR1A STK11 XPC
CDK4 ERCC6 HOXB13 NF2 PTCH1 SUFU XRCC2
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cancer diagnosis compared to the synchronous/meta-
chronous cancer group (47.7 vs 54.4, p = 0.079). All
other clinical parameters evaluated were similar in the
BC and BC-TC groups. It is worth noting that no differ-
ence was found in the frequency of the different BC
treatment modalities (irradiation, hormone or
chemotherapy).
The results of the genetic analyses for the BC-TC pa-
tients and the control group are presented in Tables 3
and 4 respectively. Details of the statistical analysis are
reported in Table 5.
We found a significantly lower number of SNPs with
potential or known association with breast cancer in the
BC only group (mean difference − 0.58, BCa 95% CI [−
1.09, − 0.06], t (27) = − 2.30, p = 0.029, g = 0.74 for un-
weighted and mean difference − 0.36, BCa 95% CI [−
0.70, − 0.02], t(27.26) = − 2.17, p = 0.039, g = 0.70 for
weighted scores).
The individual number of SNPs with no known gen-
etic association with cancer was nominally higher in the
BC only group (mean difference 0.46, BCa 95% CI [−
0.27, 1.20], t(25.56) = 1.30, p = 0.206, g = 0.39), while the
number of potentially associated SNP or those with a
known association was nominally lower in the BC only
group (mean difference − 0.92, BCa 95% CI [− 2.01,
0.17], t(30.98) = − 1.72, p = 0.096, g = 0.59 and mean dif-
ference − 0.27, BCa 95% CI [− 0.63, 0.09], t(31.37) = −
1.55, p = 0.131, g = 0.51, respectively).
When we lumped together SNPs with potential or
known association with carcinogenesis to increase statis-
tical power, we found significantly higher values in the
synchronous/metachronous cancer group compared to
Table 2 Patient characteristics at BC diagnosis and at follow-up
BC only BC and TC p-
valueMean / No of cases SD / % Mean / No of cases SD / %
No. of patients 15 19
Age at follow-up 67.3 9.2 62.3 10.5 0.16
BC clinical characteristics
Age at BC diagnosis 47.7 10.2 54.4 11.2 0.079
BC grade 0.363
1 3 37.5% 3 20% 1
2 1 12.5% 6 40% 0.104
3 4 50% 6 40% 1
BC T stage 0.393
1 4 36.4% 7 58.3% 0.715
2 6 54.5% 5 41.7% 0.475
4 1 9.1% 0 0% 0.441
Lymph node metastasis 5 33.3% 8 42.1% 0.728
Vascular invasion 2 22.2% 2 15.4% 1
HER2-positivity 6 40% 4 21% 0.276
ER-positivity 11 73% 10 52% 0.296
PR-positivity 8 53% 8 42% 0.730
Invasive ductal carcinoma 13 86.7% 16 84.2% 1
Distant metastasis 3 20% 2 10.5% 0.634
BC radiation therapy 14 93.2% 17 89.5% 1
BC chemotherapy 10 66.7% 9 60% 1
BC hormone therapy 11 73.3% 10 62.5% 0.704
BC targeted therapy 1 6.7% 2 12.5% 1
BC relapse 4 26.7% 3 15.8% 0.672
TC clinical characteristics
Age at TC diagnosis – – 53.5 15 –
Papillary histology – – 18 94.% –
Follicular histology – – 1 5.3% –
Lymph node metastasis – – 4 21% –
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Table 3 List of any cancer (and breast cancer) related genes and unique variants identified by individual patients in the BC-TC
group. The strength of known association of each variant with oncogenesis is marked as known (**), potential (*) or no (no marker)
TC-BC patients (no. of
SNPs)
Gene (known breast cancer
gene)
SNP Effect of mutation *- potential **- known
association
T + 1 (4) POLE c.1738C > A p.His580Asn*
BUB1 c.677C > T p.Ala226Val*
WRN c.355 + 4G > C intronic*
ERCC2 c.545C > T p.Ala182Val*
T + 2 (4) SMARCA4 c.918G > C p.Gln306His*
TSC1 c.3109_3110insGCA p.Gly1037_Ser1038insSer*
BIVM-ERCC5,ERCC5 c.1954C > G, c.592C > G p.Pro652Ala, p.Pro198Ala*
NBN c.511A > G p.Ile171Val*
T + 3 (5) ATR c.2924 T > C p.Leu975Ser*
KIT c.2695A > G p.Met899Val*
BMPR1A c.563G > A p.Arg188His*
PALB2 c.522A > G p.(=)*
HOXB13 c.251G > A p.Gly84Glu**




CDK4 c.625C > T p.Arg209Cys
T + 5 (5) SMAD4 c.845A > C p.His282Pro*
XPC c.155C > T p.Ser52Leu*
VPS45 c.566A > G p.Glu189Gly*
FANCM c.527C > T p.Thr176Ile
ATM c.4388 T > G p.Phe1463Cys
T + 6 (4) ATR c.4357A > G p.Ile1453Val*
ATM c.8983C > A p.Leu2995Ile*
BRCA2 c.8755-1G > A intronic**
BRCA1 c.692C > T p.Thr231Met*
T + 7 (6) MUTYH c.1276C > T p.Arg426Cys
ATR c.4912C > T p.Gln1638Ter**
ATR c.1546A > G p.Thr516Ala*
NSD1 c.3805 T > C p.Ser1269Pro*
BRCA2 c.6968A > G p.His2323Arg*
CHEK2 c.614C > T p.Thr205Ile*
T + 8 (4) ATR c.3424A > G p.Ser1142Gly*
PDGFRA c.842C > T p.Thr281Met*
TINF2 c.488C > G p.Pro163Arg*
FLCN c.592G > A p.Asp198Asn
T + 9 (1) TERT c.1234C > T p.His412Tyr
T + 10 (6) TSC2 c.3820 T > C p.Ser1274Pro*
FANCI c.2011A > G p.Ile671Val
FANCI c.2604A > C p.Glu868Asp
MFSD3 c.1033C > T p.Arg345Cys*
BRCA2 c.1483G > C p.Ala495Pro*
BRCA2 c.4409_4410delTA p.Ile1470fs**
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the BC only group using both unweighted (mean differ-
ence − 1.19, BCa 95% CI [− 2.27, − 0.11], t(31.88) = −
2.24, p = 0.032, g = 0.76) and weighted (mean difference
− 0.73, BCa 95% CI [− 1.32, − 0.14], t(31.80) = − 2.51, p =
0.017, g = 0.83) scores.
Discussion
In our study, we found a significantly higher burden of
established and potential germline cancer risk variants
among subjects with a history of metachronous thyroid
and breast cancer compared to patients with a history of
breast cancer only. The trend was similar and effect sizes
were still considerable when we assessed the number of
SNPs with known and potential cancer risk separately.
However, in these cases, probably due to lack of power,
statistical significance was not reached. Our results are
compatible with the hypothesis that the sporadic co-
occurrence of thyroid and breast cancer is of
multigenetic origin and probably related to the burden
of the carcinogenic SNPs rather than an individual gene
alteration.
Comparison of clinical features of breast cancer, such
as onset, stage, histology and treatment also yielded no
significant differences. There was a non-significant ten-
dency for later age of breast cancer onset in the study
group which is contrary to previous findings [22].
The metachronous and synchronous occurrence of
breast and thyroid cancer has been first described nearly
four decades ago [1]. The relationship between the two
tumor types has since been found to be bidirectional. In
recent meta-analyses, the odds ratio for thyroid cancer
following breast cancer treatment was 1.55 while the
odds ratio of developing BC after TC was reported be-
tween 1.18–1.32 [3, 4]. Studies exploring the cause be-
hind this association emphasize either the role of
common underlying hormonal and environmental
Table 3 List of any cancer (and breast cancer) related genes and unique variants identified by individual patients in the BC-TC
group. The strength of known association of each variant with oncogenesis is marked as known (**), potential (*) or no (no marker)
(Continued)
TC-BC patients (no. of
SNPs)
Gene (known breast cancer
gene)
SNP Effect of mutation *- potential **- known
association
T + 11 (2) PTCH1 c.4324C > T p.Arg1442Trp
CDH1 c.32 T > C p.Leu11Pro*
T + 12 (5) PMS1 c.2783 T > C p.Leu928Pro*
ATM c.1273G > A p.Ala425Thr*
ATM c.1300C > T p.Pro434Ser*
BRCA2 c.9038C > T p.Thr3013Ile
STK11 c.413A > G p.Glu138Gly*
T + 13 (2) MUTYH c.536A > G p.Tyr179Cys**
SLX4 c.2359G > A p.Glu787Lys
T + 14 (3) FANCG c.634G > A p.Ala212Thr*
CHEK2 c.1556G > T p.Arg519Leu*
KIF1B c.2680G > A p.Val894Met*
T + 15 (2) RECQL c.1360C > T p.Arg454Cys*
CHEK2 c.444 + 1G > A intronic**
T + 16 (4) TSC1 c.2418G > A p.Met806Ile*
POLD1 c.835_837delGAG p.Glu279del*
PDGFRA c.1099G > A p.Val367Met*
DIS3L2 c.1447C > G p.Arg483Gly*
T + 17 (3) RECQL4 c.3062G > A p.Arg1021Gln
SLX4 c.3890G > A p.Gly1297Glu
SLX4 c.179A > C p.Gln60Pro
T + 18 (4) MSH6 c.3226C > T p.Arg1076Cys**
ATM c.7290 T > G p.His2430Gln*
MAX c.25G > T p.Val9Leu*
BRCA1 c.181 T > G p.Cys61Gly**
T + 19 (0) – –
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Table 4 List of any cancer (and breast cancer) related genes and unique variants identified by individual patients in the control
group. The strength of known association of each variant with oncogenesis is marked as known (**), potential (*) or no (no marker)
BC only patients (no. of SNPs) Gene (known breast cancer gene) SNP Effect of mutation *- potential **- known association
T-1 (3) ATM c.8965C > G p.Gln2989Glu*
MUTYH c.1435G > A p.Glu479Lys*
FANCB c.2435A > G p.Tyr812Cys*
T-2 (2) MSR1 c.919G > T p.Asp307Tyr*
ATM c.6067G > A p.Gly2023Arg
T-3 (4) RAD50 c.1741C > T p.His581Tyr*
MITF c.1255G > T p.Glu419Ter**
WRN c.95A > G p.Lys32Arg
APC c.7490C > T p.Ser2497Leu
T-4 (6) ELANE c.341 T > C p.Leu114Ser*
RB1 c.10A > C p.Lys4Gln*
WRN c.1149G > T p.Leu383Phe
ERCC4 c.1135C > T p.Pro379Ser
MSR1 c.667 T > A p.Ser223Thr*
WRN c.2983G > A p.Ala995Thr
T-5 (1) TSC1 c.1390G > A p.Gly464Ser*
T-6 (1) CHEK2 c.190G > A p.Glu64Lys**
T-7 (3) MSH2 c.2187G > A p.Met729Ile*
RAD50 c.734A > G p.Glu245Gly*
FANCA c.2658G > C p.Glu886Asp*
T-8 (2) CDH1 c.344C > T p.Thr115Met*
MET c.2962C > T p.Arg988Cys
T-9 (6) MDH2 c.415G > A p.Val139Ile*
FANCA c.1874G > C p.Cys625Ser
ATR c.7303A > G p.Ile2435Val*
TERT c.2726 T > C p.Val909Ala*
PALB2 c.2483G > A p.Cys828Tyr*
FANCB c.454 T > C p.Phe152Leu*
T-10 (3) RECQL4 c.616A > C p.Lys206Gln*
BLM c.3536C > T p.Thr1179Ile*
FANCC c.632C > G p.Pro211Arg
T-11 (3) MITF c.1334C > A p.Thr445Lys
WRN c.1211 T > C p.Ile404Thr
SLX4 c.179A > C p.Gln60Pro
T-12 (1) FANCI c.824 T > C p.Ile275Thr
T-13 (3) BUB1 c.307A > G p.Ile103Val
FANCA c.1874G > C p.Cys625Ser
AXIN2 c.1994delG p.Gly665fs*
T-14 (3) RECQL4 c.941C > T p.Pro314Leu
SLX4 c.4963A > G p.Arg1655Gly
RAD51C c.130 T > C p.Ser44Pro
T-15 (1) PMS1 c.1609G > A p.Glu537Lys*
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factors, or the role of the first malignancy in the devel-
opment of the second. The potential role of cancer treat-
ment and the increased surveillance of cancer survivors
fall in this latter category. With breast cancer being the
most common type of malignancy in women [23] and
with the increasing incidence of thyroid cancer world-
wide [24, 25], the importance of this topic is clear.
One potential hypothesis explaining this bidirectional
relationship implicates common hormonal factors and is
rooted in the overwhelming predominance of both can-
cer types in reproductive-aged women [4]. Estrogen,
progesterone and androgen receptors have been shown
to be overexpressed not only in breast cancer but also in
thyroid neoplasms [26]. In vitro and animal studies also
point towards the potential oncogenic effect of estrogens
in thyroid cells [26, 27]. An increased TSH secretion in
response to estrogens has also been suggested as a po-
tential pathomechanism for thyroid cancer development
[3], as serum TSH levels have been shown to correlate
with thyroid cancer risk [28]. TSH and thyroid hor-
mones also have been implicated in breast carcinogen-
esis by in vitro animal and observational studies. T3
seems to stimulate proliferation in breast cancer cells
in vitro at least in part through interactions with the es-
trogen signalling system [29, 30]. Tumor suppressor
pathways downstream of the TRβ nuclear thyroid recep-
tor and oncogenic pathways downstream of the mem-
brane receptor αVβ3 have been suggested to mediate the
role of thyroid hormones in carcinogenesis [31–33].
While some observational studies in humans found a de-
creased breast cancer incidence in hypothyroid and an
increased incidence in hyperthyroid patients [7, 8], other
studies have failed to replicate these findings [34, 35].
Endocrine disrupting chemicals (EDC) have been
linked to numerous types of hormone dependent malig-
nancies including both thyroid and breast cancer [36,
37]. In addition to EDCs, obesity, a shared risk factor for
both tumor types has also been postulated to increase
the risk of synchronous/metachronous cancer
development [38, 39]. Selective estrogen receptor modu-
lators (SERMs) are widely used in breast cancer treat-
ment. While there is some evidence that these drugs due
to their partial estrogen effect increase TSH secretion
and thyroid cell proliferation, their potential role in thy-
roid cancer development has not yet been studied [13].
The similar frequency of hormone therapy in the BC
only, and the BC-TC groups in our study point toward a
limited role of sex hormones in the development of co-
occurring breast and thyroid cancer.
Other theories suggest the role of prior cancer treat-
ment in the development of the second primary malig-
nancy. Despite several improvements minimizing
radiation scatter to surrounding tissues, there is a defin-
itely increased risk for certain malignancies following ex-
ternal beam radiation for breast cancer [40]. While some
reports are conflicting [41], most available data do not
substantiate such a connection between thyroid cancer
and previous adjuvant breast irradiation [42–45]. Simi-
larly, radioactive iodine treatment given for thyroid can-
cer does not seem to play a role in subsequent breast
cancer development [46–48]. Our data with similar fre-
quency of radiation therapy for breast cancer in the in-
vestigated groups also argue against the role of external
or internal radiation in the development of synchron-
ous/metachronous breast and thyroid cancer.
The increased co-occurrence of these tumor types
could also be related to surveillance bias. The higher
compliance with, and higher rate of screening efforts
among cancer survivors could also affect the time of
diagnosis and could lead the substantial overdiagnosis of
clinically irrelevant second primary malignancy [49].
This seems to be especially true for differentiated thy-
roid cancer [50]. However, as there are no screening
programs for breast cancer among thyroid cancer survi-
vors or vice versa, surveillance bias is unlikely to account
for the preferential association of these tumor types.
Cowden syndrome (CS) and Cowden-like syndromes
(CLS) are characterised by hamartomas and an
Table 5 Comparison of the two patient groups by the number of genetic variants
BC only BC and TC p-
valueMean Std. error Mean Std. error
Genes associated with BC
No. of SNPs with potential/ known association with BC 0.27 0.12 0.84 0.22 0.029
No. of SNPs with potential/ known association with BC (weighted scores) 0.17 0.08 0.53 0.15 0.039
112 cancer risk genes
No. of SNPs with no known association with oncogenesis 1.20 0.30 0.74 0.20 0.206
No. of SNPs with a potential association with oncogenesis 1.40 0.39 2.32 0.37 0.096
No. of SNPs with a known association with oncogenesis 0.20 0.11 0.47 0.14 0.131
No. of SNPs with potential/ known association with oncogenesis 1.60 0.36 2.79 0.39 0.032
No. of SNPs with potential and known association with oncogenesis (weighted scores) 0.90 0.18 1.63 0.23 0.017
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extremely increased risk for several types of malignan-
cies including breast cancer, thyroid cancer, endometrial
cancer, colorectal cancer, and melanoma with standard-
ized incidence ratios for breast and thyroid cancer in the
range of 6 to 9 [14]. CS and most forms of CLS have an
autosomal dominant inheritance. However, these condi-
tions, referred to as PTEN hamartoma tumor syn-
dromes, make up only a small fraction of synchronous/
metachronous thyroid and breast cancer cases. This is
consistent with our finding that no patient in our sam-
ples had a mutation in the PTEN gene. Thus, the exist-
ence of other shared genetic risk factors is highly
probable. To the best of our knowledge, genetic analyses
exploring this notion have not been conducted and gen-
etic factors underlying sporadic metachronous cancer
cases are yet to be elucidated.
The main strengths of this study were the state-of-the-
art genetic analysis using NGS technology, and the fact
that both cases and controls came from the same source
population. The main limitation of our research was the
relatively low number of patients limiting statistical
power even in analyses of genetic scores. Furthermore,
our study was unable to identify or investigate any single
genetic risk locus behind synchronous/metachronous
cancer development. Two types of bias could also have
affected our findings. First, participants were recruited
years after diagnosis potentially leading to survivor bias.
Second, the exclusion of controls with less than 12 years
of follow-up lead to an age difference between our study
groups that is contrary to previous findings [22], and
probably reflects selection bias. However, both of these
selections were deemed to be necessary to minimize
contamination of the control group with thyroid cancer.
Conclusions
In conclusion, we reported an increased burden of car-
cinogenic SNPs in people with both thyroid and breast
cancer compared to individuals with breast cancer only,
based on whole exome sequencing of 112 known heredi-
tary cancer risk genes. We found no differences in clini-
copathologic parameters between the groups suggesting
that both groups have similar presentation at the time of
diagnosis of breast cancer. While our study was not
powered to identify specific risk loci for metachronous
cancer development, our findings further support the
multigenetic etiology of co-occurring breast and thyroid
cancer. Our findings do not directly contradict any of
the other, previously detailed theories explaining the as-
sociation between these tumor types. Nevertheless, our
results do underline the need for further genetic re-
search in this field, which are lacking at the moment.
Abbreviations
BC: Breast cancer; BCa 95% CI: Bias-corrected and accelerated 95% bootstrap
confidence interval; CLS: Cowden-like syndromes; CS: Cowden syndrome;
EDC: Endocrine disrupting chemical; hCG: Human chorionic gonadotropin;
IGV: Integrative genomics viewer; ISP: Ion sphere particles; SD: Standard





BB1, AK, PL, and IT conceived of the presented idea. All authors were
involved in planning and supervising the work. BB1, BB2, AK, PL, MD, ZsV
supervised sample and data collection. Genetic data collection, analysis and
interpretation were carried out by KÁ, BB2, BT, and JK. Statistical analysis was
done by ÁT, BSz, BDK, and RÁ. Manuscript was drafted by BB1, AK, PL, ZsP,
and RA, and was substantively revised by MD and ZsV. All authors discussed
the results and contributed to the final manuscript. All authors read and
approved the final manuscript.
Funding
The research was financed by the FIKP and the Thematic Excellence Program
(Tématerületi Kiválósági Program, 2020–4.1.1.-TKP2020) of the Ministry for
Innovation and Technology in Hungary, within the framework of the
Molecular Biology thematic program of Semmelweis University. The funding
body had no role in the design of the study and collection, analysis, and
interpretation of data and in writing the manuscript.
Availability of data and materials
All data generated or analysed during this study are included in this
published article.
Declarations
Ethics approval and consent to participate
This research was approved and licenced by the Semmelweis University
Regional and Institutional Committee of Science and Research Ethics, and
was conducted in accordance with the World Medical Association’s
Declaration of Helsinki. Written informed consent was obtained from all
participants before entering the study and prior to any study related
procedures. This consent extended to the study team accessing their
relevant medical history and genetic data. All participants were 18 years or




The authors state that they have no competing interests.
Author details
1Department of Internal Medicine and Oncology, Semmelweis University
Faculty of Medicine, 1098 Korányi S. u. 2/a, Budapest, Hungary. 2First
Department of Medicine, University of Szeged Faculty of Medicine, Szeged,
Hungary. 3Department of Epidemiology and Public Health, University College
London, London, UK. 4Department of Public Health, Semmelweis University
Faculty of Medicine, Budapest, Hungary.
Received: 25 October 2020 Accepted: 18 May 2021
References
1. McTiernan A, Weiss NS, Daling JR. Incidence of thyroid cancer in women in
relation to known or suspected risk factors for breast cancer. Cancer Res.
1987;47(1):292–5.
2. An JH, Hwangbo Y, Ahn HY, Keam B, Lee KE, Han W, et al. A possible
association between thyroid Cancer and breast Cancer. Thyroid. 2015;25(12):
1330–8. https://doi.org/10.1089/thy.2014.0561.
3. Nielsen SM, White MG, Hong S, Aschebrook-Kilfoy B, Kaplan EL, Angelos P,
et al. The breast-thyroid Cancer link: a systematic review and meta-analysis.
Cancer Epidemiol Biomark Prev. 2016;25(2):231–8. https://doi.org/10.1158/1
055-9965.EPI-15-0833.
Bakos et al. BMC Cancer          (2021) 21:706 Page 9 of 11
4. Joseph KR, Edirimanne S, Eslick GD. The association between breast cancer
and thyroid cancer: a meta-analysis. Breast Cancer Res Treat. 2015;152(1):
173–81. https://doi.org/10.1007/s10549-015-3456-6.
5. Moleti M, Sturniolo G, Di Mauro M, Russo M, Vermiglio F. Female
Reproductive Factors and Differentiated Thyroid Cancer. Front Endocrinol
(Lausanne). 2017;8:111.
6. Hardefeldt PJ, Eslick GD, Edirimanne S. Benign thyroid disease is associated
with breast cancer: a meta-analysis. Breast Cancer Res Treat. 2012;133(3):
1169–77. https://doi.org/10.1007/s10549-012-2019-3.
7. Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, et al.
Thyroid hormone and breast carcinoma. Primary hypothyroidism is
associated with a reduced incidence of primary breast carcinoma. Cancer.
2005;103(6):1122–8. https://doi.org/10.1002/cncr.20881.
8. Shi XZ, Jin X, Xu P, Shen HM. Relationship between breast cancer and levels
of serum thyroid hormones and antibodies: a meta-analysis. Asian Pac J
Cancer Prev. 2014;15(16):6643–7. https://doi.org/10.7314/APJCP.2014.15.16.
6643.
9. Kurata A. Differentiated thyroid cancer: why does it affect predominantly
women during the reproductive period and have higher incidence of
mutual association with breast cancer? Med Hypotheses. 2019;122:5–7.
https://doi.org/10.1016/j.mehy.2018.10.008.
10. Hoffman K, Lorenzo A, Butt CM, Hammel SC, Henderson BB, Roman SA,
et al. Exposure to flame retardant chemicals and occurrence and severity of
papillary thyroid cancer: a case-control study. Environ Int. 2017;107:235–42.
https://doi.org/10.1016/j.envint.2017.06.021.
11. Tunio MA, Al Asiri M, Bayoumi Y, Stanciu LG, Al Johani N, Al Saeed EF. Is
thyroid gland an organ at risk in breast cancer patients treated with
locoregional radiotherapy? Results of a pilot study. J Cancer Res Ther. 2015;
11(4):684–9. https://doi.org/10.4103/0973-1482.167613.
12. Zhang Y, Liang J, Li H, Cong H, Lin Y. Risk of second primary breast cancer
after radioactive iodine treatment in thyroid cancer: a systematic review and
meta-analysis. Nucl Med Commun. 2016;37(2):110–5. https://doi.org/10.1
097/MNM.0000000000000419.
13. Zidan J, Rubenstein W. Effect of adjuvant tamoxifen therapy on thyroid
function in postmenopausal women with breast cancer. Oncology. 1999;
56(1):43–5. https://doi.org/10.1159/000011928.
14. Ngeow J, Stanuch K, Mester JL, Barnholtz-Sloan JS, Eng C. Second malignant
neoplasms in patients with Cowden syndrome with underlying germline
PTEN mutations. J Clin Oncol. 2014;32(17):1818–24. https://doi.org/10.1200/
JCO.2013.53.6656.
15. Ni Y, He X, Chen J, Moline J, Mester J, Orloff MS, et al. Germline SDHx
variants modify breast and thyroid cancer risks in Cowden and Cowden-like
syndrome via FAD/NAD-dependant destabilization of p53. Hum Mol Genet.
2012;21(2):300–10. https://doi.org/10.1093/hmg/ddr459.
16. Bolf EL, Sprague BL, Carr FE. A linkage between thyroid and breast Cancer: a
common etiology? Cancer Epidemiol Biomark Prev. 2019;28(4):643–9.
https://doi.org/10.1158/1055-9965.EPI-18-0877.
17. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic
population-based assessment of cancer risk in first-degree relatives of
cancer probands. J Natl Cancer Inst. 1994;86(21):1600–8. https://doi.org/10.1
093/jnci/86.21.1600.
18. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe
A, et al. Comprehensive characterization of Cancer driver genes and
mutations. Cell. 2018;174(4):1034–5. https://doi.org/10.1016/j.cell.2018.07.034.
19. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med.
2008;359(20):2143–53. https://doi.org/10.1056/NEJMra0802968.
20. Shah PD, Nathanson KL. Application of panel-based tests for inherited risk
of Cancer. Annu Rev Genomics Hum Genet. 2017;18(1):201–27. https://doi.
org/10.1146/annurev-genom-091416-035305.
21. Landrum MJ, Lee JM, Benson M, Brown G, Chao C, Chitipiralla S, et al.
ClinVar: public archive of interpretations of clinically relevant variants.
Nucleic Acids Res. 2016;44(D1):D862–8. https://doi.org/10.1093/nar/gkv1222.
22. Kuo JH, Chabot JA, Lee JA. Breast cancer in thyroid cancer survivors: An
analysis of the surveillance, epidemiology, and end Results-9 database.
Surgery. 2016;159(1):23–9. https://doi.org/10.1016/j.surg.2015.10.009.
23. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;
67(1):7–30. https://doi.org/10.3322/caac.21387.
24. Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, et al.
International patterns and trends in thyroid cancer incidence, 1973-2002.
Cancer Causes Control. 2009;20(5):525–31. https://doi.org/10.1007/s10552-
008-9260-4.
25. Davies L, Welch HG. Current thyroid cancer trends in the United States.
JAMA Otolaryngol Head Neck Surg. 2014;140(4):317–22. https://doi.org/10.1
001/jamaoto.2014.1.
26. Yane K, Kitahori Y, Konishi N, Okaichi K, Ohnishi T, Miyahara H, et al.
Expression of the estrogen receptor in human thyroid neoplasms. Cancer
Lett. 1994;84(1):59–66. https://doi.org/10.1016/0304-3835(94)90358-1.
27. Rajoria S, Suriano R, Shanmugam A, Wilson YL, Schantz SP, Geliebter J, et al.
Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid.
2010;20(1):33–41. https://doi.org/10.1089/thy.2009.0296.
28. Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC,
et al. Higher serum thyroid stimulating hormone level in thyroid nodule
patients is associated with greater risks of differentiated thyroid cancer and
advanced tumor stage. J Clin Endocrinol Metab. 2008;93(3):809–14. https://
doi.org/10.1210/jc.2007-2215.
29. Hall LC, Salazar EP, Kane SR, Liu N. Effects of thyroid hormones on human
breast cancer cell proliferation. J Steroid Biochem Mol Biol. 2008;109(1–2):
57–66. https://doi.org/10.1016/j.jsbmb.2007.12.008.
30. Silva JM, Dominguez G, Gonzalez-Sancho JM, Garcia JM, Silva J, Garcia-
Andrade C, et al. Expression of thyroid hormone receptor/erbA genes is
altered in human breast cancer. Oncogene. 2002;21(27):4307–16. https://doi.
org/10.1038/sj.onc.1205534.
31. Kim WG, Cheng SY. Thyroid hormone receptors and cancer. Biochim
Biophys Acta. 2013;1830(7):3928–36. https://doi.org/10.1016/j.bbagen.2012.
04.002.
32. Martinez-Iglesias O, Garcia-Silva S, Tenbaum SP, Regadera J, Larcher F,
Paramio JM, et al. Thyroid hormone receptor beta1 acts as a potent
suppressor of tumor invasiveness and metastasis. Cancer Res. 2009;69(2):
501–9. https://doi.org/10.1158/0008-5472.CAN-08-2198.
33. Carr FE, Tai PW, Barnum MS, Gillis NE, Evans KG, Taber TH, et al. Thyroid
hormone receptor-beta (TRbeta) mediates runt-related transcription factor 2
(Runx2) expression in thyroid Cancer cells: a novel signaling pathway in
thyroid Cancer. Endocrinology. 2016;157(8):3278–92. https://doi.org/10.1210/
en.2015-2046.
34. Muller I, Kilburn LS, Taylor PN, Barrett-Lee PJ, Bliss JM, Ellis P, et al. TPOAb
and thyroid function are not associated with breast Cancer outcome:
evidence from a large-scale study using data from the Taxotere as adjuvant
chemotherapy trial (TACT, CRUK01/001). Eur Thyroid J. 2017;6(4):197–207.
https://doi.org/10.1159/000460246.
35. Fang Y, Yao L, Sun J, Yang R, Chen Y, Tian J, et al. Does thyroid dysfunction
increase the risk of breast cancer? A systematic review and meta-analysis. J
Endocrinol Investig. 2017;40(10):1035–47. https://doi.org/10.1007/s40618-01
7-0679-x.
36. Gore AC, Chappell VA, Fenton SE, Flaws JA, Nadal A, Prins GS, et al. EDC-2:
the Endocrine Society's second scientific statement on endocrine-disrupting
chemicals. Endocr Rev. 2015;36(6):E1–E150. https://doi.org/10.1210/er.2015-1
010.
37. Soto AM, Vandenberg LN, Maffini MV, Sonnenschein C. Does breast cancer
start in the womb? Basic Clin Pharmacol Toxicol. 2008;102(2):125–33.
https://doi.org/10.1111/j.1742-7843.2007.00165.x.
38. Harvie M, Howell A, Evans DG. Can diet and lifestyle prevent breast cancer:
what is the evidence? Am Soc Clin Oncol Educ Book. 2015;(35):e66–73.
https://doi.org/10.14694/EdBook_AM.2015.35.e66.
39. Ma J, Huang M, Wang L, Ye W, Tong Y, Wang H. Obesity and risk of thyroid
cancer: evidence from a meta-analysis of 21 observational studies. Med Sci
Monit. 2015;21:283–91. https://doi.org/10.12659/MSM.892035.
40. Matesich SM, Shapiro CL. Second cancers after breast cancer treatment.
Semin Oncol. 2003;30(6):740–8. https://doi.org/10.1053/j.seminoncol.2003.08.
022.
41. Grantzau T, Overgaard J. Risk of second non-breast cancer among patients
treated with and without postoperative radiotherapy for primary breast
cancer: a systematic review and meta-analysis of population-based studies
including 522,739 patients. Radiother Oncol. 2016;121(3):402–13. https://doi.
org/10.1016/j.radonc.2016.08.017.
42. Li CI, Rossing MA, Voigt LF, Daling JR. Multiple primary breast and thyroid
cancers: role of age at diagnosis and cancer treatments (United States).
Cancer Causes Control. 2000;11(9):805–11. https://doi.org/10.1023/A:1008942
616092.
43. Huang J, Walker R, Groome PG, Shelley W, Mackillop WJ. Risk of thyroid
carcinoma in a female population after radiotherapy for breast carcinoma.
Cancer. 2001;92(6):1411–8. https://doi.org/10.1002/1097-0142(20010915)92:
6<1411::AID-CNCR1464>3.0.CO;2-9.
Bakos et al. BMC Cancer          (2021) 21:706 Page 10 of 11
44. Lal G, Groff M, Howe JR, Weigel RJ, Sugg SL, Lynch CF. Risk of subsequent
primary thyroid cancer after another malignancy: latency trends in a
population-based study. Ann Surg Oncol. 2012;19(6):1887–96. https://doi.
org/10.1245/s10434-011-2193-2.
45. Kim SS, Kim SJ, Bae YT, Lee JY, Kim BH, Kim YK, et al. Factors associated with
the development of new onset diffuse thyroid F18-fluorodeoxyglucose
uptake after treatment of breast cancer in patients without a history of
thyroid disease or thyroid dysfunction. Thyroid. 2012;22(1):53–8. https://doi.
org/10.1089/thy.2011.0013.
46. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of
second primary malignancies up to three decades after the treatment of
differentiated thyroid cancer. J Clin Endocrinol Metab. 2008;93(2):504–15.
https://doi.org/10.1210/jc.2007-1154.
47. Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, et al.
Second primary malignancy risk after radioactive iodine treatment for
thyroid cancer: a systematic review and meta-analysis. Thyroid. 2009;19(5):
451–7. https://doi.org/10.1089/thy.2008.0392.
48. Verkooijen RB, Smit JW, Romijn JA, Stokkel MP. The incidence of second
primary tumors in thyroid cancer patients is increased, but not related to
treatment of thyroid cancer. Eur J Endocrinol. 2006;155(6):801–6. https://doi.
org/10.1530/eje.1.02300.
49. Ito Y, Miyauchi A, Oda H. Low-risk papillary microcarcinoma of the thyroid: a
review of active surveillance trials. Eur J Surg Oncol. 2018;44(3):307–15.
https://doi.org/10.1016/j.ejso.2017.03.004.
50. Ahn HS, Kim HJ, Welch HG. Korea's thyroid-cancer "epidemic"--screening
and overdiagnosis. N Engl J Med. 2014;371(19):1765–7. https://doi.org/10.1
056/NEJMp1409841.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Bakos et al. BMC Cancer          (2021) 21:706 Page 11 of 11
